Skip to main content

Treatment Clinical Trials for Malignant Mesothelioma

Review the malignant mesothelioma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 30

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Status: Active
Location: 13 locations
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Active
Location: 12 locations
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Status: Active
Location: 10 locations
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Status: Active
Location: 8 locations
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Status: Active
Location: 7 locations
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Status: Active
Location: 7 locations
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Status: Active
Location: 9 locations
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Status: Active
Location: 5 locations
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Status: Active
Location: 5 locations
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Status: Active
Location: 3 locations
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Status: Active
Location: 6 locations
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
Status: Active
Location: 2 locations
Magnesium for the Prevention of Kidney Damage in Patients with Mesothelioma Undergoing Surgery with Hyperthermic Intraoperative Cisplatin
Status: Active
Location: Brigham and Women's Hospital, Boston, Massachusetts
Brentuximab Vedotin in Treating Patients with CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Olaparib for the Treatment of Homologous Recombination Deficient Malignant Mesothelioma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Cell Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Solid Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Durvalumab and Tremelimumab with or without Chemotherapy for the Treatment of Potentially Resectable Pleural Mesothelioma
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Status: Active
Location: 2 locations
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Pembrolizumab in Combination with Chemotherapy and Image-Guided Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma (MPM)
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
A Surgical Procedure (Partial Pleurectomy and Decortication) for the Treatment of Borderline Resectable and Unresectable Pleural Mesothelioma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois